Originally published In Press as doi:10.1074/jbc.M002208200 on May 12, 2000
J. Biol. Chem., Vol. 275, Issue 31, 23462-23470, August 4, 2000
Nuclear Import of Insulin-like Growth Factor-binding Protein-3
and -5 Is Mediated by the Importin
Subunit*
Lynette J.
Schedlich
§,
Sophie L.
Le Page
,
Sue M.
Firth
,
Lyndall J.
Briggs¶,
David A.
Jans¶, and
Robert C.
Baxter
From the
Kolling Institute of Medical Research,
University of Sydney, Royal North Shore Hospital, Sydney, New South
Wales 2065, Australia and the ¶ John Curtin School of Medical
Research, Australian National University, Canberra,
Australian Capital Territory 2601, Australia
Received for publication, March 14, 2000, and in revised form, May 1, 2000
 |
ABSTRACT |
Although insulin-like growth factor-binding
protein (IGFBP)-3 and IGFBP-5 are known to modulate cell growth by
reversibly sequestering extracellular insulin-like growth factors,
several reports have suggested that IGFBP-3, and possibly also IGFBP-5, have important insulin-like growth factor-independent effects on cell
growth. These effects may be related to the putative nuclear actions of
IGFBP-3 and IGFBP-5, which we have recently shown are transported to
the nuclei of T47D breast cancer cells. We now describe the mechanism
for nuclear import of IGFBP-3 and IGFBP-5. In digitonin-permeabilized
cells, where the nuclear envelope remained intact, nuclear
translocation of wild-type IGFBP-3 appears to occur by a nuclear
localization sequence (NLS)-dependent pathway mediated
principally by the importin
nuclear transport factor and requiring
both ATP and GTP hydrolysis. Under identical conditions, an NLS mutant
form of IGFBP-3, IGFBP-3[228KGRKR
MDGEA], was
unable to translocate to the nucleus. In cells where both the plasma
membrane and nuclear envelope were permeabilized, wild-type
IGFBP-3, but not the mutant form, accumulated in the nucleus,
implying that the NLS was also involved in mediating binding to nuclear
components. By fusing wild-type and mutant forms of NLS sequences
(IGFBP-3 [215-232] and IGFBP-5 [201-218]) to the green
fluorescent protein, we identified the critical residues of the NLS
necessary and sufficient for nuclear accumulation. Using a Western
ligand binding assay, wild-type IGFBP-3 and IGFBP-5, but not an NLS
mutant form of IGFBP-3, were shown to be recognized by importin
and
the
/
heterodimer but only poorly by importin
. Together these
results suggest that the NLSs within the C-terminal domain of IGFBP-3
and IGFBP-5 are required for importin-
-dependent nuclear
uptake and probably also accumulation through mediating binding to
nuclear components.
 |
INTRODUCTION |
The mitogenic effects of insulin-like growth factors
(IGFs)1 are modulated by a
family of IGF-binding proteins (IGFBPs). Following their secretion into
the extracellular environment, the IGFBPs inhibit or stimulate cell
growth by regulating access of the extracellular IGFs to the type I IGF
receptor (1). However, some IGFBPs, including IGFBP-3, also have
effects on cell growth that are type I receptor-independent (2, 3).
Expression of recombinant human IGFBP-3, for example, has been shown to
inhibit the proliferation of murine fibroblasts with a targeted
disruption to the type I receptor (4). This growth inhibitory effect
was directly related to the induction of apoptosis by IGFBP-3 (5). In
addition, a number of potent growth-inhibitory and apoptosis-inducing
agents such as transforming growth factor
1, retinoic acid, tumor
necrosis factor-
, and anti-estrogens also induce IGFBP-3 gene
expression (6, 7). These effects on cell growth may be mediated by IGFBP-3 in an IGF-independent manner. There are fewer reports of
IGF-independent effects of IGFBP-5; these include its ability to
stimulate bone cell growth in the absence of increased IGF-I binding to
its receptor (8). The mechanism(s) for the IGF-independent effects of
IGFBP-3 and IGFBP-5 are currently unknown but may involve a direct
nuclear action.
Although some proteins appear to be constitutively nuclear, others
enter the nucleus only under defined conditions (9). Thus, cells are
able to control the activity of nuclear proteins by regulating their
nuclear uptake during differentiation and changes in the metabolic
state of the cell. The central pore of the nuclear pore complex allows
molecules up to 45 kDa to move freely between the nuclear and
cytoplasmic compartments (10). For proteins larger than 45 kDa, nuclear
transport is generally an active, nuclear localization sequence
(NLS)-dependent process that requires specific targeting
sequences contained within the primary sequence of the transported
protein or a cotransported protein (11).
The cell contains multiple signal-dependent pathways for
nuclear transport, of which the best characterized requires the
cytosolic receptors, importin
and
(12), the monomeric guanine
nucleotide-binding protein, Ran (13-15), and interacting proteins such
as nuclear transport factor 2 (16-18). Conventionally, the importin
subunit acts as an adapter, binding to the NLS of cytosolic
proteins as well as to importin
, which together with Ran effects
translocation through the nuclear pore complex. The importin
/
heterodimer recognizes three different classes of NLS: those that
contain basic residues arranged as a single stretch (e.g.
the NLS of the SV40 large tumor antigen, T-ag) (9, 19, 20) or as two
clusters of basic residues separated by a spacer region (bipartite NLS) (9, 21) or those resembling the NLS of the yeast homeodomain protein
Mat
2 (22). Other signal-dependent pathways have been described that include the transport of proteins that bind directly to
and are transported by members of the importin
family (in this
pathway the adapter, importin
, is not required to effect nuclear
transport) (23-25) and those that do not require soluble cytosolic
receptors at all but appear to require ATP (26-28).
Significantly, in the context of IGF-independent nuclear action, the
C-terminal regions of IGFBP-3 and IGFBP-5 contain a domain with strong
sequence homology to the bipartite NLS consensus motif (29). This basic
domain is highly conserved in IGFBP-3 and IGFBP-5 from different
species, suggesting that it has functional significance. Similar basic
sequences have been identified in a number of other secreted proteins
and shown to be important for their respective signaling roles. These
include platelet-derived growth factor A (30), acidic fibroblast growth
factor (31), and parathyroid hormone-related protein (32). We and
others have described the nuclear transport of IGFBP-3 and IGFBP-5 in a
number of cell lines (33-36).
As part of our investigation into the role of nuclear IGFBP-3 and
IGFBP-5, the present study examines the mechanisms for their nuclear
import. We report that previously identified NLS-like sequences within
IGFBP-3 and IGFBP-5 are necessary and sufficient for their nuclear
accumulation. IGFBP-3 nuclear import is an energy-dependent process requiring ATP and GTP hydrolysis and mediated by importin
.
In addition, IGFBP-3 and IGFBP-5 are both recognized specifically by
importin
and the importin
/
heterodimer but not by importin
. Thus, nuclear import of IGFBP-3, and by analogy IGFBP-5, appears to occur by a signal-dependent importin
-mediated
pathway. In addition, we show that, possibly mediated by its NLS,
IGFBP-3 is capable of interaction with nuclear binding sites, which
may play an important role in its nuclear accumulation.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Recombinant human IGFBP-3 and
IGFBP-3[228KGRKR
MDGEA] were produced by a
replication-deficient adenovirus-mediated expression system, as
described previously (37). IGFBP-3 was purified from conditioned
media by IGF-I affinity chromatography and reverse-phase high
pressure liquid chromatography (38). In studies requiring fluorescently labeled IGFBP-3, the protein was conjugated to
dichlorotriazinylaminofluorescein I HCl as described previously for Cy3
(35). The fusion proteins generated by linking
-galactosidase to the
bipartite NLS derived from the Xenopus laevis
phosphoprotein, N1N2 (N1N2 NLS:
-gal), or the T-ag NLS were
expressed, purified, and, where appropriate, fluorescently labeled with
5-iodoacetamidofluorescein as described previously (39). Recombinant
human IGFBP-5 was a generous gift from J. Zapf (Zürich,
Switzerland). IGFBP-1 was purified from human amniotic fluid (40),
recombinant human IGFBP-2 was provided by Sandoz (Basel, Switzerland),
and IGF-I was provided by Genentech (South San Francisco, CA).
Antiserum against IGFBP-3 was prepared in this laboratory following
immunization of rabbits with purified antigen, and the monoclonal
antibody specific for importin
(mAb3E9, from purified ascites
fluid) was from S. Adam (Chicago, IL).
Dichlorotriazinylaminofluorescein I HCl was purchased from Research
Organics and 5-iodoacetamidofluorescein and Texas Red-dextran (~70
kDa) were purchased from Molecular Probes. Creatine phosphokinase,
creatine phosphate, ATP, and FITC-dextran (~77 kDa), leupeptin,
apyrase, GTP
S, CHAPS, Triton X-100, and RIA grade BSA were obtained
from Sigma.
In Vitro Nuclear Transport Assay--
In vitro
nuclear transport was carried out as described previously (41). Chinese
hamster ovary (CHO) cells were cultured on glass coverslips, washed
with ice-cold transport buffer (50 mM Hepes/KOH, pH 7.3, 110 mM potassium acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 1 mM EGTA, and 1 mM dithiothreitol), and permeabilized with 50 µg/ml
digitonin (Calbiochem) for 5 min on ice. The cells were washed with
transport buffer, and the coverslips were inverted over 20 µl of
transport buffer containing either IGFBP-3 (5 ng/µl) or N1N2
NLS:
-gal (0.2 µg/µl) with 45 mg/ml rabbit reticulocyte lysate
(RRL) (Promega), an ATP-regenerating system (0.125 mg/ml creatine
phosphokinase, 30 mM creatine phosphate, 2 mM
ATP), and 200 µg/ml Texas Red or FITC-labeled dextran. Although no
RRL-induced proteolysis of IGFBP-3 was detected by Western immunoblotting (data not shown), 1 µg/ml leupeptin, 25 units/ml trasylol (Bayer), and 40 µg/ml bestatin (Roche) were routinely added
as protease inhibitors to the transport assay. The cells were incubated
in a humidified environment for 30 min at 22 °C.
For competition experiments, RRL was incubated at 22 °C for 30 min
with an excess of unlabeled IGFBP-3 prior to the addition of labeled
IGFBP-3. Where RRL was omitted, 0.25% BSA was included in the
transport buffer. For studies carried out in the absence of an
ATP-regenerating system, apyrase was used to pretreat cells (0.2 unit/ml, 37 °C, 15 min), and RRL (800 units/ml, 22 °C, 10 min)
was used to remove endogenous ATP. To investigate the role of importin
in IGFBP-3 nuclear import, the transport assay was carried out
in the presence of an anti-importin
antibody (80 µg/ml) without
the addition of RRL. The role of GTP hydrolysis in nuclear import of
IGFBP-3 was examined by preincubating RRL with the nonhydrolyzable GTP
analogue, GTP
S (2 mM), for 10 min at 22 °C. When
added to the cells, the final concentration of GTP
S was 300 µM. To assess the contribution to nuclear accumulation of
binding to nuclear components, the nuclear envelope was permeabilized by addition of 0.025% CHAPS in 2 mM Tris·HCl, pH 7.0, and 1% glycerol to the transport solution (42), and the duration of
the assay was reduced to 10 min at 22 °C.
For transport assays using labeled IGFBP-3 or N1N2 NLS:
-gal,
fluorescence was detected directly following fixation of the cells.
Where unlabeled IGFBP-3 was used, the subcellular localization was
determined using indirect immunocytochemistry. Cells were fixed using
Histochoice (Amresco), the nuclear envelope was permeabilized with
0.25% Triton X-100, and the cells were blocked with 1% BSA in
phosphate-buffered saline for 1 h at 22 °C. The cells were then
incubated with antiserum against IGFBP-3 or nonimmune rabbit serum
(1:5000) diluted in blocking buffer for 1 h at 22 °C. Cells were then washed and incubated with goat anti-rabbit IgG conjugated with rhodamine (Immunotech) diluted 1:200 in blocking buffer for 1 h at 22 °C. Cells were mounted in an antifade medium and examined using a confocal laser scanning microscopic (CLSM) system (Optiscan F900e Personal Confocal System, Victoria, Australia) fitted with a
krypton-argon laser and dual channel detection optics. Individual cells
were optically sectioned in the xy plane with multiple scan averaging. All images were collected under identical, nonsaturating conditions. The intensity of fluorescent labeling within cells was
analyzed using the program NIH Image version 1.61. Pixel intensity, as
a measure of fluorescence intensity, was measured within specific regions of the cell (cytoplasmic and nuclear) as well as in regions outside the cell (background). The pixel intensity from each
subcellular region was averaged over at least 100 cells. After
correction for background fluorescence, the results were expressed as
the ratio of nuclear to cytoplasmic fluorescence (Fn/c).
Construction of EGFP Fusion Proteins--
A 1080-base pair
EcoRI-PvuII fragment containing the full coding
sequence of human IGFBP-3 was inserted into pSELECT (Promega) to
generate pSF106 (38). Site-directed mutagenesis of pSF106 was
carried out with the following oligonucleotides to introduce specific
mutations: 5'-CCCAACTGTGACAAGAACGGATTTTATAAGAAAAAGC was used to generate pSF184 (216K
N);
5'-GTGACAAGAAGGGATTTTATCACTCCCGCCAGTGTCGCCCTTCCAAAGG
was used to generate pSF170 (220KKK
HSR) and
5'-TTTTATAAGAAAAAGCAGTGTCGCCCTTCCATGGACGGGGAGGCGGGCTTCTGCTGGTGTGTGGATAAGTATGGG to generate pSF110 (228KGRKR
MDGEA). Nucleotides
that differ from the IGFBP-3 sequence are underlined. The cDNA
for human IGFBP-5 was generated from total RNA isolated from U2-OS
osteosarcoma cell-line by reverse transcription-polymerase chain
reaction. The resulting 868-base pair fragment containing the full
coding sequence of IGFBP-5 was inserted into pAC-CMV to generate pSF601.
Oligonucleotides containing KpnI and BamHI
restriction sites for subcloning were synthesized on an Oligo 1000 DNA
Synthesizer (Beckman Instruments). Fragments containing the 18-amino
acid wild-type or mutant NLSs of IGFBP-3 or IGFBP-5 were amplified by
Pfu turbo polymerase (Stratagene) and cloned into the EGFP C-terminal fusion vector, pEGFP-C1 (CLONTECH).
The wild-type IGFBP-3 NLS was amplified from pSF106 using primers 1 and
2 and wild-type IGFBP-5 NLS was amplified from pSF601 using primers 3 and 4 (Table I). The mutant
216K
N(BP-3) was amplified from pSF184
using primers 2 and 5, and 202K
N(BP-5) was
amplified from pSF601 using primers 4 and 6. The mutant
215KK
AA(BP-3) was amplified from pSF106
using primers 2 and 7, and 201RK
AA(BP-5)
was amplified from pSF601 using primers 4 and 8. The mutant
220KKK
HSR(BP-3) was amplified from pSF170
using primers 2 and 9, and 206KRK
HSR(BP-5)
was amplified from overlapping oligonucleotides 10 and 11. The mutant
228KGRKR
MDGEA(BP-3) was amplified from
pSF110 using primers 1 and 12, and 214RGRKR
MDGEA(BP-5) was amplified from pSF601 using primers 3 and
13. All mutations within the 18-amino acid basic region of IGFBP-3 and
IGFBP-5 (except the N-terminal double alanine mutants) are based on
the corresponding sequences in IGFBP-1.
View this table:
[in this window]
[in a new window]
|
Table I
Nucleotide sequence of primers used to generate IGFBP-3 and IGFBP-5 NLS
mutants
Restriction sites are in bold. Nucleotides that differ from the
wild-type IGFBP-3 or IGFBP-5 sequences are underlined.
|
|
The IGFBP-3 double mutant 216K
N and 220KKK
HSR(BP-3) was amplified from pSF170 using primers 2 and
5, and the double mutant 216K
N and
228KGRKR
MDGEA(BP-3) was amplified from
pSF110 using primers 5 and 12. Following amplification, all polymerase
chain reaction products were cloned inframe into the KpnI
and BamHI restriction sites of pEGFP-C1 and checked by sequencing.
Cell Culture and Transient Transfection--
CHO cells were
maintained in
-modification of Eagle's medium supplemented
with 10% fetal calf serum (Cytosystems). For transient transfection,
CHO cells were cultured on glass coverslips in 6-well dishes. At
70-80% confluence, 2 µg of EGFP fusion plasmid was transfected into
cells using LipofectAMINE (Life Technologies) according to the
manufacturer's instructions. At 24 h after transfection, cells
were fixed with Histochoice for 20 min, mounted in an antifade medium,
and scored using an Olympus BX60 fluorescent microscope.
Statistical Analysis--
Data were analyzed by analysis of
variance followed by Fisher's protected least significant difference
test using Statview 4.02 (Abacus Concepts, Inc.).
Dot Blot and Western Ligand Binding Assays--
Binding of
IGFBP-3 and IGFBP-5 to importin subunits was examined by dot blot or
Western ligand binding assays as described previously (43). The mouse
- and
-importin subunits were expressed as glutathione
S-transferase fusion proteins and purified as described previously (43). The binding proteins and controls were applied directly to a nitrocellulose membrane (dot blot) or separated on 10%
SDS-polyacrylamide gel electrophoresis prior to membrane transfer
(Western ligand blot). The two different approaches allowed these
studies to be carried out with the binding proteins in their native
(dot blot) and denatured forms (Western ligand blot). Where indicated,
IGFBP-3 was preincubated with an equimolar amount of IGF-I before
application in the dot blot assay. The membranes were blocked in
intracellular buffer containing 5% BSA for 4 h at 22 °C and
hybridization at 4 °C for 16 h in intracellular buffer containing 1% BSA and either a preformed complex of mouse
and
importin subunits fused to glutathione S-transferase (1:1
molar ratio) at a final concentration of 150 nM or with the
individual subunits alone at the same concentration. Binding of
importins to IGFBPs was detected using a glutathione
S-transferase-specific antibody (Amersham Pharmacia
Biotech), followed by an alkaline phosphatase-conjugated secondary
antibody (Sigma) and nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-1-phosphate (Promega) (dot blot)
or a horseradish peroxidase-conjugated secondary antibody (Amersham
Pharmacia Biotech) and ECL (Amersham Pharmacia Biotech) (Western ligand
blot). In the case of the latter, imaging was carried out using a
Fujifilm FLA-3000 Gel Imager, with quantitation performed using the
Image Gauge 3.11 software.
 |
RESULTS |
Nuclear Import of IGFBP-3 Is a Specific and Saturable
Process--
NLS-dependent nuclear protein import is an active
process requiring cytosolic factors including importin
/
, Ran,
and interacting factors (44). Because IGFBP-3 (40-45-kDa glycosylated
doublet) is close to the theoretical limit for diffusion into the
nucleus, we investigated whether nuclear import could occur by a
conventional NLS-mediated pathway. An in vitro nuclear
transport assay was used in which the plasma membrane of CHO cells was
permeabilized with the weak nonionic detergent digitonin, leaving the
nuclear envelope intact (41). Nuclear transport of fluorescently
labeled IGFBP-3 was examined in the presence of a transport solution
containing RRL (a source of cytosolic proteins), an ATP-regenerating
system (to provide energy for translocation), and fluorescently
labeled-dextran (to control for membrane integrity). The subcellular
distribution of the fluorescent signal was determined using CLSM. In
all cells where the plasma membrane had been permeabilized but where
the nuclear envelope remained intact (fluorescently labeled dextran being specifically excluded from the nucleus), IGFBP-3 was localized to
the cell nuclei (Fig. 1A).
Quantitation using NIH Image version 1.61 (see "Experimental
Procedures") showed that IGFBP-3 accumulated in the nucleus at levels
4.7-fold greater than in the cytoplasm (Fig. 1D).

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 1.
Nuclear import of IGFBP-3 is a specific and
saturable process. Following permeabilization of the plasma
membrane, CHO cells were incubated in transport solution containing
cytosol, an ATP-regenerating system and fluorescently labeled IGFBP-3
without (A, nil) or with a 10-fold (B)
or 20-fold (C) excess of unlabeled IGFBP-3. The images were
collected using CLSM and are representative of three independent
experiments. Scale bar, 50 µm. Quantitation was carried
out using NIH Image, and the results were expressed as the ratio of
nuclear to cytoplasmic fluorescence (Fn/c) ± S.E. (D).
|
|
To demonstrate that nuclear import of IGFBP-3 was a specific and
saturable process, we competed fluorescently labeled IGFBP-3 with
unlabeled IGFBP-3. Cytosol was preincubated with a 10- or 20-fold
excess of unlabeled IGFBP-3 prior to the addition of fluorescently labeled IGFBP-3. Results of the in vitro nuclear transport
assay showed that the nuclear to cytoplasmic fluorescence ratio was reduced to 2.6-fold in the presence of a 10-fold excess of unlabeled IGFBP-3 (Fig. 1, B and D). Following
preincubation with a 20-fold excess of unlabeled IGFBP-3 (Fig.
1C), this was further reduced to 1.5-fold (Fig.
1D), close to an Fn/c value of
1.0 representing equal fluorescence in the nucleus and cytoplasm.
Therefore, an Fn/c value of 1.5 suggests that
little nuclear fluorescence was detectable following the addition of a
20-fold excess of unlabeled IGFBP-3.
Nuclear Transport of IGFBP-3 Is an Energy-dependent
Process Mediated by the Importin
Subunit--
The role of
individual components of the nuclear transport pathway can be examined
by their selective addition to the in vitro nuclear
transport assay. We compared the nuclear uptake of IGFBP-3 with that of
N1N2 NLS:
-gal, which is transported to the nucleus by the
conventional NLS-mediated nuclear protein import pathway utilizing Ran
and the importin
/
heterodimer (45, 46). Following nuclear
transport, the subcellular localization of unlabeled IGFBP-3 was
monitored using indirect immunocytochemistry, the control protein was
directly fluorescently labeled, and both were detected using
CLSM.
As was observed for fluorescently labeled IGFBP-3 (Fig. 1A),
all cells with an intact nuclear envelope contained nuclear IGFBP-3 (Fig. 2A). When specific
IGFBP-3 antiserum was replaced with nonimmune rabbit serum in similarly
treated cells, only light background labeling was detected, indicating
that the signal was specific to IGFBP-3 (data not shown). As previously
shown, the N1N2 NLS directed nuclear accumulation of
-galactosidase
(Fig. 2A) (46). In the absence of an ATP-regenerating
system, both IGFBP-3 and N1N2 NLS:
-gal were localized to the
cytoplasm, being generally excluded from the nucleus (Fig.
2B). A requirement for ATP in NLS-dependent
nuclear import has been described for a number of proteins (26,
42).

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 2.
Nuclear import of IGFBP-3 is an
energy-dependent process mediated by the
importin- subunit.
Digitonin-permeabilized CHO cells were incubated with IGFBP-3 and N1N2
NLS: -gal (a control for the conventional importin / -mediated
nuclear import pathway directed by a bipartite NLS) and visualized by
CLSM. In vitro nuclear transport (see "Experimental
Procedures") was carried out in the presence of cytosol and an
ATP-regenerating system (A). The effect on nuclear transport
of omitting the ATP-regenerating system (B) or cytosol
(C) was examined. Transport studies were also carried out in
the presence of an anti-importin- antibody without the addition of
cytosol (D) and following preincubation of cytosol with the
nonhydrolyzable GTP analogue GTP S (E). Images are
representative of at least three independent experiments. Scale
bar, 50 µm.
|
|
When cytosolic proteins (in the form of RRL) were omitted from the
transport solution, the pattern of nuclear accumulation of IGFBP-3
(Fig. 2C) was indistinguishable from that seen in its presence (Fig. 2A). Therefore, in contrast to N1N2
NLS:
-gal, which demonstrated cytosol-dependent nuclear
transport (Fig. 2C), nuclear import of IGFBP-3 was
independent of exogenously added cytosol. Previous studies have shown
that although importin
is released following treatment of cells
with digitonin, sufficient importin
may remain to sustain basal
nuclear import (12, 47, 48). Therefore, the independence of nuclear
uptake of IGFBP-3 on cytosolic factors suggests that importin
is
not required for nuclear import, whereas the possibility remains that
importin
may act alone as the transport receptor for IGFBP-3.
NLS-dependent nuclear import, where the transported protein
binds directly to importin
independently of importin
, has been
documented for a number of proteins (23-25, 49).
Nuclear import of IGFBP-3 was examined following neutralization of
importin
from the assay by the addition of an anti-importin
antibody in the absence of RRL. Results showed a significant reduction
in the level of nuclear import of both IGFBP-3 and N1N2 NLS:
-gal
(Fig. 2D). Because no importin
was added to the system in this experiment, the results suggest that importin
is unlikely to have a role in IGFBP-3 nuclear import. In a similar experiment where
RRL was preincubated with the anti-importin
antibody prior to
addition to the assay, nuclear import of IGFBP-3 was also reduced (data
not shown). The role of GTP hydrolysis in nuclear transport of IGFBP-3
was examined following preincubation of the cytosol with the
nonhydrolyzable GTP analogue, GTP
S. Again nuclear accumulation of
both IGFBP-3 and N1N2 NLS:
-gal was reduced in the presence GTP
S
(Fig. 2E), with the pattern of IGFBP-3 labeling similar to
that observed for cells treated with the anti-importin
antibody (Fig. 2D). These results suggest that nuclear accumulation
of IGFBP-3 is an active process with a requirement for both importin
and GTP hydrolysis in its nuclear transport and appears to be independent of importin
. In addition, because some nuclear uptake of IGFBP-3 remains (Fig. 2D), other uptake/accumulation
mechanisms may be operating in addition to that utilizing importin
.
Although the cytosol-independent nature of IGFBP-3 nuclear import
implies that a role for Ran is unlikely, other GTP-binding proteins may be involved in nuclear protein import, and the action of these proteins
may constitute the basis of the inhibition of IGFBP-3 nuclear import by
GTP
S. Alternatively, Ran may not have been fully depleted from the
transport assay following permeabilization of the cells.
Nuclear Accumulation of IGFBP-3 Is Prevented When the Putative NLS
Is Mutated or Lost by Proteolytic Cleavage--
We have previously
shown that the mutant, IGFBP-3[228KGRKR
MDGEA],
obtained by exchanging part of the putative NLS of IGFBP-3 for the
corresponding sequences in IGFBP-1, is not transported to the nucleus
of intact cells (35). However, we have also shown that this IGFBP-3
mutant is unable to bind at the cell surface (38), leading to the
speculation that transport to the nucleus may be blocked at the level
of the plasma membrane rather than at the level of entry into the
nucleus. To address this issue, we compared nuclear uptake of wild-type
and mutant IGFBP-3 (in cells were the plasma membrane had been
permeabilized) using the fully reconstituted in vitro
nuclear transport assay. In contrast to wild-type IGFBP-3 (Fig.
3A), the mutant,
IGFBP-3[228KGRKR
MDGEA], was not localized to the
nucleus (Fig. 3B), suggesting that residues 228-232 within
the basic region of IGFBP-3 are indeed required for nuclear
accumulation as well as plasma membrane binding.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 3.
Nuclear accumulation of IGFBP-3 is prevented
when the putative NLS is mutated or lost by proteolytic cleavage.
Nuclear transport of wild-type IGFBP-3 (A) was compared with
the mutant IGFBP-3[228KGRKR MDGEA] (B) and
a 30-kDa N-terminal proteolytic fragment of IGFBP-3 (C).
In vitro nuclear transport was carried out in
digitonin-permeabilized CHO cells in the presence of a fully
reconstituted transport system. Images were collected using CLSM and
are representative of three independent experiments. Scale
bar, 50 µm.
|
|
During an early round of purification of wild-type IGFBP-3, a 30-kDa
proteolytic fragment was generated. The purified fragment was subject
to N-terminal sequencing and shown to be an N-terminal fragment of
IGFBP-3. It therefore lacks the basic region present in the C-terminal
domain of the protein. When nuclear uptake was examined, this truncated
form of IGFBP-3 did not accumulate in the nucleus (Fig. 3C).
Therefore, with respect to nuclear transport, the proteolytic fragment
behaved in a similar fashion to the mutant form of IGFBP-3, supporting
the observation that sequences within the C-terminal domain are
required for active nuclear transport.
IGFBP-3 Binds to Insoluble Nuclear Components--
In the presence
of a permeabilized nuclear envelope, soluble proteins are able to pass
freely between the cytoplasm and nucleus. Under these circumstances,
nuclear accumulation occurs only if the protein binds to insoluble
nuclear components (42). To investigate whether IGFBP-3 was capable of
such interactions, we used the in vitro transport assay on
cells where the nuclear envelope had been permeabilized with the
detergent CHAPS. To demonstrate that CHAPS was effectively
permeabilizing the nuclear envelope, experiments were carried in the
presence of FITC-dextran (molecular mass, ~77 kDa). Under
these conditions FITC-dextran distributes evenly between the nucleus
and cytoplasm. In the presence of a fully reconstituted assay and the
absence of a barrier to nuclear entry, nuclear accumulation of
wild-type IGFBP-3 was observed (Fig.
4A). The same field of cells
visualizing the FITC-dextran signal (Fig. 4B) showed that
accumulation of IGFBP-3 only occurred in those cells with a perforated
nuclear envelope. In contrast, N1N2 NLS:
-gal did not accumulate in
the nucleus, instead equilibrating between the nuclear and cytoplasmic
compartments (data not shown). Nuclear accumulation of the mutant
IGFBP-3[228KGRKR
MDGEA] was also examined following
permeabilization of the nuclear envelope; under these conditions the
mutant failed to accumulate in the nuclei of cells with a permeabilized
nuclear envelope (Fig. 4, C and D). These results
indicate that, in contrast to the conventional NLSs, the IGFBP-3 NLS
contains sequences capable of conferring nuclear accumulation in the
absence of an intact nuclear envelope, presumably through interaction
with nuclear components.

View larger version (108K):
[in this window]
[in a new window]
|
Fig. 4.
IGFBP-3 binds to insoluble nuclear
components. Following permeabilization of both the plasma membrane
and the nuclear envelope, nuclear accumulation of wild-type IGFBP-3
(A) and the IGFBP-3 mutant, 228KGRKR MDGEA (C) was examined in the presence of cytosol and an
ATP-regenerating system. The distribution of FITC-dextran in the same
field of cells is shown for wild-type (B) and mutant
(D) IGFBP-3. Arrows indicate nonpermeabilized
cells. The images were collected using CLSM and are representative of
three independent experiments. Nuclear accumulation indicates binding
to detergent-insoluble nuclear components. Scale bar, 50 µm.
|
|
The NLSs of IGFBP-3 and IGFBP-5 Are Capable of Targeting a
Heterologous Protein to the Nucleus--
In a previous study we showed
that both IGFBP-3 and IGFBP-5 are transported to the cell nucleus in
intact cells (35). The ability of the putative NLS regions within
IGFBP-3 and IGFBP-5 to target EGFP to the nucleus was examined by
fusing these sequences to EGFP and expressing the resultant fusion
protein in CHO cells. EGFP is a 27-kDa protein and as such is capable
of passive diffusion into the nucleus (50). Nuclear accumulation occurs
only if EGFP is fused to sequences that confer active nuclear import or
nuclear binding. Transfected cells were scored in two categories: where the nuclear and cytoplasmic fluorescent intensity was equivalent (no
nuclear accumulation) and where the nuclear signal was greater than the
cytoplasmic signal (nuclear accumulation). Expression of EGFP alone
resulted in only a small percentage of cells (7.3%) with a nuclear
signal greater than that observed in the cytoplasm (Fig.
5A and Table
II). However, expression of the wild-type
IGFBP-3 NLS (residues 215-232) fused to EGFP resulted in 92.8% of
cells where nuclear was greater than cytoplasmic intensity (Fig.
5B). Likewise, when the wild-type IGFBP-5 NLS (residues
201-218) was fused to EGFP, 96.9% of cells had accumulated EGFP in
the nucleus (Fig. 5C). From this data we conclude that these
18-residue basic sequences within the C-terminal domains of IGFBP-3
and IGFBP-5 are sufficient for nuclear uptake of the binding
proteins.

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 5.
The basic regions of IGFBP-3 and IGFBP-5
direct the nuclear import of an heterologous protein. Plasmids
expressing the native EGFP (A) and EGFP fused to the
putative NLSs of IGFBP-3 (B) or IGFBP-5 (C) were
transiently transfected and expressed in CHO cells and visualized by
fluorescent microscopy. Likewise, EGFP fused to the corresponding
18-amino acid region of IGFBP-3 containing the mutation
228KGRKR MDGEA (D) and this region of
IGFBP-5 containing the mutation 214RGRKR MDGEA
(E) were also expressed in CHO cells. Images are
representative of at least four independent experiments. Scale
bar, 25 µm.
|
|
To identify which residues within these sequences were necessary for
nuclear accumulation, we mutated each of the three basic clusters
within the NLS to the corresponding sequences in IGFBP-1 (a binding
protein we have shown is not transported to the nucleus) and fused
these mutant sequences to EGFP (Table II). The mutations 216K
N(BP-3) and 202K
N(BP-5) did not affect nuclear transport of the fusion
protein giving 83.3 and 89.3% of cells, respectively, with nuclear
greater than cytoplasmic fluorescence; these values are not
significantly different from those seen for the wild-type sequences. A
more radical mutation of IGFBP-3 and IGFBP-5 within the first basic
cluster, where both the basic residues were substituted with alanine,
215KK
AA(BP-3) and 201RK
AA(BP-5), had a significant effect on nuclear transport
(Table II), suggesting that the sequence responsible for nuclear
accumulation had a bipartite nature. The mutations 220KKK
HSR(BP-3) and 206KRK
HSR(BP-5) also had a significant effect on nuclear
transport of the fusion protein giving 62.2 and 55.2% of cells,
respectively, with nuclear greater than cytoplasmic signal. The
mutations 228KGRKR
MDGEA(BP-3) (Fig.
5D) and 214RGRKR
MDGEA(BP-5)
(Fig. 5E) abolished nuclear accumulation of the fusion
protein, giving 1.2 and 0.3% of cells, respectively, with nuclear
greater than cytoplasmic fluorescence (Table II). As expected, a double mutation of the IGFBP-3 NLS, which involved the first and third basic
cluster prevented nuclear transport of the fusion protein (Table II).
Mutation of both the first and second basic clusters resulted in a
further decrease in nuclear transport (40.3%) of the fusion protein
compared with the central mutant alone (62.2%). Together these results
suggest that the sequences 228KGRKR(BP-3) and
214RGRKR(BP-5) are essential for nuclear import
of the binding proteins but that the other basic residues within the
NLS probably contribute to the overall efficiency of nuclear accumulation.
IGFBP-3 and IGFBP-5 Are Recognized by the Importin
/
Heterodimer through the Importin
Subunit--
The
and
importin subunits constitute the high affinity NLS receptor used by
many proteins to effect their nuclear import (12). The ability of
full-length IGFBPs to be recognized by importin subunits was examined
using dot blot (Fig. 6A) and
Western ligand binding analysis (Fig. 6B) (43) to examine
interactions of native and denatured binding proteins, respectively.
Wild-type IGFBP-3 showed strong binding by the importin complex
(Fig. 6, A, lane 6, and B, top
panel). This binding was of a similar intensity to that obtained
for the T-ag NLS:
-galactosidase fusion protein (positive control)
(Fig. 6A, lane 2). In contrast, the NLS mutant, IGFBP-3[228KGRKR
MDGEA], displayed weaker binding by
the importin
/
heterodimer NLS (Fig. 6, A, lane
5, and B, top panel) compared with wild-type IGFBP-3. However, this binding appeared to be stronger than that obtained for
-galactosidase, which does not contain an NLS (negative control) (Fig. 6A, lane 1). Of the other binding
proteins tested, IGFBP-5 was also recognized by the importin
heterodimer (Fig. 6B, top panel). IGFBP-1 and
IGFBP-2, which are not translocated to the nucleus in intact cells
(35), showed no detectable binding by the importin complex (data not
shown).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
IGFBP-3 and IGFBP-5 are recognized by the
importin /
heterodimer through the importin subunit. IGFBPs and controls were applied directly to
membrane (A) or separated on 10% SDS-polyacrylamide gel
electrophoresis prior to membrane transfer (B) and
hybridization with a complex of importin / (A and
B, top panels) or individual importin subunits
(B, middle and bottom panels). The
amount of protein added is indicated as pmol (A) or µg
(B), and the positions of molecular mass markers are
indicated. Control proteins were -galactosidase (negative control)
(A, lane 1) and the T-ag NLS fused to
-galactosidase (positive control) (A, lane 2).
The binding proteins analyzed were wild-type IGFBP-3 (A,
lane 6, and B, lanes 1 and
2), the IGFBP-3 NLS mutant, 228KGRKR MDGEA
(A, lane 5, and B, lanes 3 and 4) and wild-type IGFBP-5 (B, lanes
5 and 6). An equimolar amount of IGF-I was preincubated
with either wild-type (A, lane 4) or the mutant
form of IGFBP-3 (A, lane 3) prior to membrane
application. Quantitation of the Western ligand blot was carried out
using a Fujifilm FLA-3000 Imager and the Image Gauge software
(C), where the mean signal intensities ± S.E.
(n = 4) for importin and importin are expressed
as percentages of those for binding by importin / .
|
|
Because IGFBP-3 has been shown to act as a carrier for IGF-I nuclear
transport (34), we investigated whether the binary complex would bind
more strongly to the importin subunits. However, when equimolar amounts
of IGFBP-3 and IGF-I were equilibrated and subjected to dot blotting,
there was no discernible difference in binding of either wild-type
(Fig. 6A, lane 4) or mutant IGFBP-3 (Fig.
6A, lane 3) to the importin complex compared with
these proteins in the absence of IGF-I (Fig. 6A, lanes
5 and 6). In addition, when IGF-I was added to the
hybridization mix containing importin
/
, there was no change in
the binding of importin to wild-type or mutant IGFBP-3 analyzed by
Western ligand binding (data not shown).
Because nuclear transport of IGFBP-3 appears to be mediated by importin
(independently of importin
), we examined whether the observed
importin
/
heterodimer binding was mediated by the importin
(Fig. 6B, middle panel) or
(Fig.
6B, bottom panel) subunit. The Western ligand
binding assay clearly showed that IGFBP-3 and IGFBP-5 were both
recognized by importin
(Fig. 6B, bottom
panel). In contrast, neither binding protein was recognized to any
great extent by importin
(Fig. 6B, middle
panel), nor did mutant IGFBP-3 exhibit significant binding to
either importin subunit (Fig. 6B, middle and
bottom panels). Quantitation of binding indicated that, in
the case of IGFBP-3, importin
binding accounted for almost 40% of
the binding of the importin heterodimer (Fig. 6C). Although
importin
binding to IGFBP-3 represented only a small proportion of
importin
/
binding, it was still an appreciable amount compared
with importin
binding only. However, in the case of IGFBP-5,
importin
binding accounted for essentially all of the binding of
the importin heterodimer (Fig. 6C). The mutant form of
IGFBP-3 displayed less than 50% binding to the importin
/
heterodimer and the individual importin subunits, compared with
wild-type IGFBP-3. It was concluded that importin
, but not importin
, was able to recognize IGFBP-3 and IGFBP-5 and that there appeared
to be a quantifiable difference in importin subunit binding to these IGFBPs.
 |
DISCUSSION |
This study identifies an 18-amino acid region of IGFBP-3 and
IGFBP-5 that is necessary and sufficient for nuclear transport and
accumulation. Our results suggest that nuclear import of IGFBP-3, and
probably by analogy IGFBP-5, is an energy-dependent process mediated by importin
and following nuclear entry, IGFBP-3 can actively accumulate through binding to detergent-insoluble nuclear components. Mutation of the basic regions within the C-terminal domain
of IGFBP-3 and IGFBP-5 attenuates nuclear import and/or accumulation
and, as shown for IGFBP-3, reduces importin binding.
We have studied nuclear transport of IGFBP-3 using an in
vitro nuclear transport assay that allows the role of individual components of the transport system to be examined. As a control, we
examined the nuclear uptake of
-galactosidase fused to the N1N2
bipartite NLS (46). In the presence of cytosolic factors and an
ATP-regeneration system, full-length wild-type IGFBP-3 was capable of
nuclear uptake in all cells where the plasma membrane had been
permeabilized, but the nuclear envelope remained intact. Previous
studies in intact cells have shown that nuclear transport of IGFBP-3 is
detected only in a low percentage of cells in the monolayer (33-36).
Therefore, these data suggest that the plasma membrane is an important
regulator of nuclear uptake of IGFBP-3 and consequently also of its
subsequent function in the nucleus.
Nuclear protein import directed by bipartite NLSs conventionally
requires cytosolic factors such as importin
/
, Ran, and nuclear
transport factor 2 (44). However, we show here that nuclear transport
of IGFBP-3 can occur efficiently in the absence of added soluble
transport factors. Analogous observations have been reported for
nuclear transport conferred by the HIV-I Tat NLS (26) and the
heterogeneous nuclear ribonucleoprotein (hnRNP) K sequence KNS (28).
The Wnt signal transduction pathway component
-catenin (27), which
appears to be able to bind directly to nucleoporins, similarly appears
not to require soluble factors for nuclear import; interestingly,
nuclear transport of
-catenin appears to occur through a
Ran-independent pathway (51). However, unlike IGFBP-3, the targeting
signals of Tat and hnRNP K represent novel nuclear targeting signals
not resembling the T-ag or bipartite NLSs and, furthermore, do not
appear to be recognized by importin
/
. Previous studies have
found that sufficient importin
, but not importin
, may remain
associated with the nuclear pore complex to support a basal level of
nuclear import subsequent to digitonin permeabilization (12, 47, 48).
Therefore, nuclear import in the absence of added cytosol suggests that
the adapter, importin
, is not required for nuclear transport but
does not rule out the possibility that importin
alone is mediating
uptake. Our findings that inclusion of an antibody specific to importin
, both in the presence and absence of added cytosol, inhibited
nuclear import of IGFBP-3, suggests that importin
, but not importin
, is required to sustain basal nuclear import. Similarly, addition of the nonhydrolyzable GTP analogue, GTP
S, to the transport assay significantly reduced nuclear import of IGFBP-3. Together these results
suggest that both importin
alone, and GTP hydrolysis are required
for efficient transport. Importin
appears to be the sole nuclear
targeting signal receptor used by parathyroid hormone-related protein
(24), T-cell protein tyrosine phosphatase (25), and the yeast
transcription factor, GAL4 (23). Finally, we cannot exclude the
possibility that the cytosolic-independent nature of IGFBP-3 nuclear
import is effected by other factors that, like importin
, may not be
completely solubilized during digitonin permeabilization.
Nuclear import mediated by conventional NLSs such as those found in
T-ag and retinoblastoma (42), as well as by novel NLSs of HIV-I Tat
(26) and the hnRNP K (28) and hnRNP A1 M9 sequences (52), has been
shown to be ATP-dependent; cytosolic factor-independent nuclear import of
-catenin has also been shown to require ATP (27).
In the case of HIV-I Tat, ATP hydrolysis is believed to effect its
release from cytoplasmic retention factors and enhance binding to
nuclear components. Because nuclear import of IGFBP-3 was not observed
in the absence of an ATP-regenerating system, IGFBP-3 may also require
ATP for cytoplasmic release and/or enhanced nuclear binding.
Alternatively, as is the case for many proteins transported to the
nucleus, ATP may be involved in other, unknown actions that augment
nuclear uptake.
In the presence of a permeabilized nuclear envelope, proteins are free
to diffuse between the cytoplasmic and nuclear compartments and are
only able to accumulate in the nucleus through binding to insoluble
nuclear components such as chromatin and lamin (42). Under conditions
where the nuclear envelope was permeabilized, IGFBP-3, but not the
mutant, IGFBP-3[228KGRKR
MDGEA], was capable of
nuclear accumulation. These results support the proposal that, upon
entry into the nucleus, IGFBP-3 accumulates through nuclear binding and
suggest that residues 228-232 are required for these nuclear
interactions. The ability of IGFBP-3 to bind to structures within the
nucleus supports the hypothesis that it may have a role in the nucleus,
possibly in direct regulation of gene transcription (33-36). This has
been suggested for granzyme A and B (53, 54) and parathyroid
hormone-related protein (24), which can also accumulate in the nucleus
even in the absence of an intact nuclear envelope.
Fusion of EGFP to isolated motifs has been used to study changes in
subcellular distribution directed by these sequences (50). Using this
approach, we investigated the role of the basic motifs of IGFBP-3 and
IGFBP-5 in their nuclear transport. As the fusion proteins are
expressed in living CHO cells, the proteins, factors and metabolic
pathways present and active in living cells are able to exert their
effects on nuclear transport, thus representing an in vivo
nuclear transport assay. EGFP is small enough to enter the nucleus by
passive diffusion, and as expected, the fluorescent signal derived from
recombinant EGFP expressed in CHO cells was evenly distributed between
the nucleus and cytoplasm. Fusion of the basic region within the
C-terminal domain of IGFBP-3 and IGFBP-5 to EGFP caused nuclear
accumulation of the fusion protein in greater than 90% of transfected
cells, indicating that the basic regions are sufficient for nuclear
import. However, these results do not distinguish between active
nuclear transport and nuclear binding. Thus, there may be passive
diffusion into the nucleus followed by accumulation resulting from
interaction between these basic sequences and nuclear binding sites, as
well as interaction of the basic residues with importins, leading to
active nuclear import.
Mutation of the three basic clusters within the putative NLS of IGFBP-3
and IGFBP-5 caused different degrees of attenuation of nuclear
transport of the EGFP fusion proteins. As was observed for the mutant
form of full-length IGFBP-3, 228KGRKR
MDGEA, the same
mutation of both the IGFBP-3 and IGFBP-5 NLS when fused to EGFP,
abolished nuclear uptake of EGFP. Mutation of both amino acids within
the N-terminal basic cluster had a significant effect on nuclear
transport of the EGFP fusion proteins, suggesting that the basic region
may represent a classical bipartite NLS similar to that described for
other proteins (9, 21). However, mutation of the central basic cluster
reduced nuclear transport of the fusion proteins by approximately 60%,
implying that these basic clusters also influence nuclear accumulation and that the NLS is more complex than a classical bipartite NLS. As
discussed above, the ability of the fusion protein to diffuse freely
into the nucleus means that a distinction cannot be drawn between
enhancement of nuclear import and accumulation because of nuclear
binding. Therefore, mutations affecting nuclear transport may relate to
either or both effects. However, in vitro studies on the
mutant, IGFBP-3[228KGRKR
MDGEA], suggest these
sequences are involved in both effects. In this assay the basic
sequences derived from IGFBP-5 behaved identically to those derived
from IGFBP-3, suggesting that IGFBP-5, which is small enough to
diffusion through the nuclear pore complex (molecular mass, 30 kDa),
accumulates in the nucleus by a similar mechanism.
We found that the importin
subunit recognized both wild-type
IGFBP-3 and IGFBP-5 but recognized only to a limited extent the mutant
form of IGFBP-3. This suggests that transport of these binding proteins
occurs by a signal-mediated pathway, consistent with the observation
that importin
is required to effect in vitro nuclear
transport of IGFBP-3. Interestingly, all the importin
/
binding
to IGFBP-5 could be accounted for by importin
binding, whereas for
IGFBP-3 importin
binding appeared significantly lower compared with
its binding to the heterodimer. This was not compensated for by an
appropriate increase in importin
binding. The explanation for this
is unclear but may relate to differing affinities or accessibility of
the binding proteins for the importin subunits. Alternatively, importin
may be binding to importin
in this assay and increasing the
strength of its interactions with IGFBP-3. However, an essential
role for importin
in IGFBP-3 nuclear transport is not supported by
our findings that nuclear import occurs in the absence of exogenous cytosol.
An interesting question raised by this study is why IGFBP-5, and to a
lesser extent IGFBP-3, possess functional NLSs when, because of their
size, they have the potential to diffuse from the cytoplasm into the
nucleus. There are several reasons why smaller proteins possess
NLS-dependent mechanisms for nuclear import. As has been
described for interleukin-5 (55), a functional NLS enables the
cotransport of larger non-NLS containing proteins to the nucleus. In
analogous fashion, IGFBP-3 or IGFBP-5 may possess functional NLSs to
facilitate entry when part of a high molecular mass complex. Thus, they
may require an NLS-dependent mechanism when cotransporting
IGFs or other signaling molecules to the nucleus. Interestingly, a
preliminary report suggests that IGFBP-3 interacts specifically with
the retinoic acid X receptor-
(56). IGFBP-3 may thereby modulate the
activity of nuclear transcription factors or have a specific signal
transduction role in the nucleus. It may also regulate gene expression
directly by binding to chromatin as has been reported for basic
fibroblast growth factor (57) and the growth hormone receptor (58).
Apart from the selective use of an NLS-dependent mechanism
for the transport of high molecular mass complexes, the kinetics of
nuclear import of IGFBP-3 and IGFBP-5 may be enhanced by their ability
to interact effectively with importin. A major focus of future work in
this laboratory is to distinguish between these possibilities.
Understanding of the mechanisms of nuclear import of IGFBP-3 and
IGFBP-5 should greatly assist in defining their nuclear functions.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Phil Poronnik and David
Cook for providing the adenoviral system for expression of wild-type
and mutant IGFBP-3. We also thank Prof. Jürgen Zapf
(Zürich, Switzerland) for providing the recombinant human IGFBP-5
used in this study and Chenoa Barton for skilled technical assistance.
This research has been facilitated by access to the Australian Proteome
Analysis Facility.
 |
FOOTNOTES |
*
This work was supported by the Sydney University Medical
Foundation and the National Health and Medical Research Council. The
CLSM was purchased with the support of the Wellcome Trust.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Kolling Inst. of
Medical Research, Royal North Shore Hospital, St. Leonards, New South
Wales 2065, Australia. Tel.: 61-2-9926-8486; Fax: 61-2-9926-8484; E-mail: lyns@med.usyd.edu.au.
Published, JBC Papers in Press, May 12, 2000, DOI 10.1074/jbc.M002208200
 |
ABBREVIATIONS |
The abbreviations used are:
IGF, insulin-like
growth factor;
IGFBP, insulin-like growth factor-binding protein;
NLS, nuclear localization signal;
T-ag, SV40 large tumor antigen;
N1N2
NLS:
-gal,
-galactosidase fused to the NLS derived from N1N2;
RRL, rabbit reticulocyte lysate;
CLSM, confocal laser scanning microscopy;
EGFP, enhanced green fluorescent protein;
hnRNP, heterogeneous nuclear
ribonucleoprotein;
FITC, fluorescein isothiocyanate;
GTP
S, guanosine
5'-O-(3-thiotriphosphate);
CHAPS, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-sulfonate;
BSA, bovine serum albumin;
CHO, Chinese hamster ovary.
 |
REFERENCES |
| 1.
|
De Mellow, J. S.,
and Baxter, R. C.
(1988)
Biochem. Biophys. Res. Commun.
156,
199-204
|
| 2.
|
Cohen, P.,
Lamson, G.,
Okajima, T.,
and Rosenfeld, R. G.
(1993)
Mol. Endocrinol.
7,
380-386
|
| 3.
|
Oh, Y.,
Muller, H. L.,
Lamson, G.,
and Rosenfeld, R. G.
(1993)
J. Biol. Chem.
268,
14964-14971
|
| 4.
|
Valentinis, B.,
Bhala, A.,
DeAngelis, T.,
Baserga, R.,
and Cohen, P.
(1995)
Mol. Endocrinol.
9,
361-367
|
| 5.
|
Rajah, R.,
Valentinis, B.,
and Cohen, P.
(1997)
J. Biol. Chem.
272,
12181-12188
|
| 6.
|
Martin, J. L.,
Ballesteros, M.,
and Baxter, R. C.
(1992)
Endocrinology
131,
1703-1710
|
| 7.
|
Martin, J. L.,
Coverley, J. A.,
Pattison, S. T.,
and Baxter, R. C.
(1995)
Endocrinology
136,
1219-1226
|
| 8.
|
Mohan, S.,
Nakao, Y.,
Honda, Y.,
Landale, E.,
Leser, U.,
Dony, C.,
Lang, K.,
and Baylink, D. J.
(1995)
J. Biol. Chem.
270,
20424-20431
|
| 9.
|
Jans, D. A.,
and Hubner, S.
(1996)
Physiol. Rev.
76,
651-685
|
| 10.
|
Dingwall, C.,
and Laskey, R.
(1992)
Science
258,
942-947
|
| 11.
|
Miller, M.,
Park, M. K.,
and Hanover, J. A.
(1991)
Physiol. Rev.
71,
909-949
|
| 12.
|
Gorlich, D.,
Kostka, S.,
Kraft, R.,
Dingwall, C.,
Laskey, R. A.,
Hartmann, E.,
and Prehn, S.
(1995)
Curr. Biol.
5,
383-392
|
| 13.
|
Gorlich, D.,
Pante, N.,
Kutay, U.,
Aebi, U.,
and Bischoff, F. R.
(1996)
EMBO J.
15,
5584-5594
|
| 14.
|
Moore, M. S.,
and Blobel, G.
(1993)
Nature
365,
661-663
|
| 15.
|
Melchior, F.,
Paschal, B.,
Evans, J.,
and Gerace, L.
(1993)
J. Cell Biol.
123,
1649-1659
|
| 16.
|
Moore, M. S.,
and Blobel, G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10212-10216
|
| 17.
|
Paschal, B. M.,
and Gerace, L.
(1995)
J. Cell Biol.
129,
925-937
|
| 18.
|
Nehrbass, U.,
and Blobel, G.
(1996)
Science
272,
120-122
|
| 19.
|
Kalderon, D.,
Richardson, W. D.,
Markham, A. F.,
and Smith, A. E.
(1984)
Nature
311,
33-38
|
| 20.
|
Koepp, D. M.,
and Silver, P. A.
(1996)
Cell
87,
1-4
|
| 21.
|
Robbins, J.,
Dilworth, S. M.,
Laskey, R. A.,
and Dingwall, C.
(1991)
Cell
64,
615-623
|
| 22.
|
Hall, M. N.,
Hereford, L.,
and Herskowitz, I.
(1984)
Cell
36,
1057-1065
|
| 23.
|
Chan, C. K.,
Hubner, S.,
Hu, W.,
and Jans, D. A.
(1998)
Gene Ther.
5,
1204-1212
|
| 24.
|
Lam, M. H.,
Briggs, L. J.,
Hu, W.,
Martin, T. J.,
Gillespie, M. T.,
and Jans, D. A.
(1999)
J. Biol. Chem.
274,
7391-7398
|
| 25.
|
Tiganis, T.,
Flint, A. J.,
Adam, S. A.,
and Tonks, N. K.
(1997)
J. Biol. Chem.
272,
21548-21557
|
| 26.
|
Efthymiadis, A.,
Briggs, L. J.,
and Jans, D. A.
(1998)
J. Biol. Chem.
273,
1623-1628
|
| 27.
|
Fagotto, F.,
Gluck, U.,
and Gumbiner, B. M.
(1998)
Curr. Biol.
8,
181-190
|
| 28.
|
Michael, W. M.,
Eder, P. S.,
and Dreyfuss, G.
(1997)
EMBO J.
16,
3587-3598
|
| 29.
|
Radulescu, R. T.
(1994)
Trends Biochem. Sci.
19,
278
|
| 30.
|
Bejcek, B. E.,
Li, D. Y.,
and Deuel, T. F.
(1989)
Science
245,
1496-1499
|
| 31.
|
Imamura, T.,
Engleka, K.,
Zhan, X.,
Tokita, Y.,
Forough, R.,
Roeder, D.,
Jackson, A.,
Maier, J. A.,
Hla, T.,
and Maciag, T.
(1990)
Science
249,
1567-1570
|
| 32.
|
Henderson, J. E.,
Amizuka, N.,
Warshawsky, H.,
Biasotto, D.,
Lanske, B. M.,
Goltzman, D.,
and Karaplis, A. C.
(1995)
Mol. Cell. Biol.
15,
4064-4075
|
| 33.
|
Jaques, G.,
Noll, K.,
Wegmann, B.,
Witten, S.,
Kogan, E.,
Radulescu, R. T.,
and Havemann, K.
(1997)
Endocrinology
138,
1767-1770
|
| 34.
|
Li, W.,
Fawcett, J.,
Widmer, H. R., |